Air pollution data can be accessed from the National Air Pollution Monitoring System (<http://106.37.208.233:20035/>). Meteorological data can be accessed from the China Meteorological Data Sharing Service System (<http://data.cma.cn/>). Hospital admission data were obtained from the Hospital Quality Monitoring System (HQMS) (<https://www.hqms.org.cn/>) and cannot be made publicly available due to ethical and legal restrictions. These routinely collected healthcare data, though anonymized and de-identified, contain potentially identifying or sensitive patient information. Data that are not directly identifying, including the date of admission, clinical diagnosis, and demographic information, can become identifying in combination. According to the Personal Information Protection Law in the People's Republic of China, these data cannot be shared publicly. The data are available upon request for researchers who meet the criteria for access to confidential data. Data requesters are required to submit a research proposal to the scientific committee of the HQMS via the Scientific Project Management System (<https://spms.hqms.org.cn/>), under the regulation of Bureau of Medical Administration, National Health Commission of the People's Republic of China. The research proposal should address: (1) the background and rationale of the proposed research project; (2) the scope of the relevant data (eg, the list of relevant data items, time range, hospital scope, and the list of relevant ICD-10 codes); (3) the significance of the expected results in terms of informing public health policy makers. The scientific committee of the HQMS will review the research proposal to ensure the appropriateness of its intended use, and the data will be available if the proposal is approved. For more information and for technical assistance, please contact the HQMS staff (<service@hqms.org.cn>).

Introduction {#sec007}
============

Air pollution has become a public health concern worldwide, with exposure linked to increased morbidity and mortality \[[@pmed.1003188.ref001]--[@pmed.1003188.ref004]\]. Criteria air pollutants include fine particulate matter of 2.5 μm or less in aerodynamic diameter (PM~2.5~), tropospheric ozone (O~3~), sulfur dioxide (SO~2~), nitrogen dioxide (NO~2~), and carbon monoxide (CO). In particular, PM~2.5~ and O~3~ were used by the Global Burden of Disease Study as the 2 indicators to quantify population exposure to air pollution when estimating the global burden of disease attributable to ambient air pollution, since they were the most consistent and robust predictors of adverse outcomes in previous studies \[[@pmed.1003188.ref005]\].

The health effects of air pollution on the circulatory and respiratory systems are well documented \[[@pmed.1003188.ref006],[@pmed.1003188.ref007]\]. There is emerging evidence for increased risk of some non-cardiorespiratory diseases related to air pollution, e.g., diabetes, autism in children, dementia in the elderly, and premature birth and low birthweight \[[@pmed.1003188.ref008],[@pmed.1003188.ref009]\]. Several recent studies also revealed positive associations between air pollution and certain diseases of the digestive, skeletal, and urinary systems, e.g., peptic ulcer bleeding \[[@pmed.1003188.ref010]\], bone loss over time and bone fracture \[[@pmed.1003188.ref011]\], and incident chronic kidney disease and progression to end-stage renal disease \[[@pmed.1003188.ref012]--[@pmed.1003188.ref014]\]. There are at least 3 hypotheses to explain the extrapulmonary effects of air pollution. First, inhaled pollutants may induce pulmonary inflammation and oxidative stress, which is sufficient to cause systemic inflammation and oxidative stress \[[@pmed.1003188.ref006],[@pmed.1003188.ref015]\]. Second, the lung autonomic nervous system may be provoked by pulmonary exposure, which could then result in autonomic nervous system imbalance \[[@pmed.1003188.ref015]\]; the levels of stress hormones may also be altered \[[@pmed.1003188.ref016]\]. Third, the pollutants may reach and directly interact with remote organs, e.g., by penetrating the alveoli and entering the circulation \[[@pmed.1003188.ref017],[@pmed.1003188.ref018]\]. However, the epidemiological evidence is still scarce and inconclusive for many diseases, and is usually subject to small data size, limited representativeness, and possible publication bias. There are few studies that have characterized the health effects of air pollution on multiple organ systems using uniform methodology and databases.

China has a population of more than 1.3 billion being exposed to relatively high levels of air pollution. In recent years, China has gradually built up high-quality national databases for inpatient discharge registration, which, combined with national monitoring networks of ambient air quality, provide an opportunity to systematically investigate possible ways in which air pollution exposure may be associated with severe illnesses requiring hospitalization. In this study, we performed a nationwide time-series analysis based on hospital admissions in 252 Chinese cities from 2013 to 2017, to assess the associations between short-term exposure to main air pollutants (PM~2.5~ and O~3~) and cause-specific risk of hospital admission on a national scale. Diseases were classified by 2 approaches at different granularities. Potential effect modifiers and exposure--response relationships were also evaluated.

Methods {#sec008}
=======

Data collection {#sec009}
---------------

The daily hospital admission data during the period January 1, 2013, to December 31, 2017, came from the Hospital Quality Monitoring System (HQMS), a national registration database of electronic inpatient discharge records of class 3 hospitals in China, under the administration of the National Health Commission of the People's Republic of China. Class 3 hospitals are the highest ranked medical institutions in China's healthcare system, corresponding to tertiary hospitals in the US and Europe but also providing primary and secondary care to less serious patients. In Western countries, healthcare resource utilization is generally scheduled by appointment. However, there is no general-practitioner-based referral system in China \[[@pmed.1003188.ref019],[@pmed.1003188.ref020]\]. Regular outpatient visits and hospital admissions are generally unscheduled and are on a first-come, first-served basis. People usually go to hospital promptly when they develop symptoms and will be admitted immediately if necessary. Ninety-five percent of the total Chinese population was covered by social health insurance schemes by the end of 2017 \[[@pmed.1003188.ref021]\]. Therefore, hospital admission records can provide reliable and timely information on the health status of a geographically defined population in China. Since January 1, 2013, class 3 hospitals in China have been mandated to automatically submit inpatient discharge records to the HQMS on a daily basis, in a nationally standardized format. Each record describes a hospital stay using 346 information items, from which we extracted the date of admission, sex, age, and the primary discharge diagnosis. The diagnosis is coded using the International Classification of Diseases, 10th Revision (ICD-10) \[[@pmed.1003188.ref022]\] by certified professional medical coders at each hospital. Quality control is automatically performed at the time of submission to guarantee the completeness, consistency, and accuracy of data. By December 31, 2017, the HQMS covered 1,001 (67.0%) class 3 hospitals and 1,011,375 (78.4%) hospital beds in 252 Chinese cities. The population, the total number of class 3 hospitals, the number of class 3 hospitals covered by the HQMS, the total number of hospital beds, the number of hospital beds covered by the HQMS, and the coverage rates of class 3 hospitals and hospital beds by the HQMS in each of the 252 cities are presented in [S1 Table](#pmed.1003188.s015){ref-type="supplementary-material"}. This database has been used to track the epidemiological situation and trends of several diseases in China \[[@pmed.1003188.ref023]--[@pmed.1003188.ref025]\].

To clearly characterize the health effects of air pollution over a wide spectrum of human diseases, we defined the disease categories at 2 levels. Major disease categories are based on the chapter division (first-level classification) of the ICD-10 diagnostic coding system \[[@pmed.1003188.ref022]\]. Specifically, we treated each ICD-10 chapter as a candidate category and assigned each diagnosis code to the ICD-10 chapter that it belongs to. There are 22 ICD-10 chapters in total, of which the first 14 were included in the scope of this study (14 major disease categories). Minor disease categories are based on the Clinical Classifications Software (CCS), a validated approach developed by the Agency for Healthcare Research and Quality \[[@pmed.1003188.ref026]\]. The CCS is a comprehensive categorization scheme for aggregating diagnosis codes into a manageable number of disease categories on the basis of clinical homogeneity, and has been widely used to examine patterns of specific health conditions \[[@pmed.1003188.ref027],[@pmed.1003188.ref028]\]. All diagnosis codes were collapsed into 260 mutually exclusive CCS categories, of which we selected as candidates 191 that conceptually belonged to the 14 major disease categories. We excluded 3 categories (CCS codes 56, 61, and 75) that had too few data, leaving 188 as the final set of minor disease categories. For each cause (major or minor disease category), we obtained the daily counts of citywide hospital admissions by summing the daily number of admissions for primary diagnosis of this cause in each hospital in a city. All data used were anonymized and de-identified prior to analysis, under the supervision of Bureau of Medical Administration, National Health Commission of the People's Republic of China. Because the data were analyzed at the aggregate level with no individual identifiers involved, institutional review board approval and participant written consent were not required for this study.

The daily air pollution data came from the National Air Pollution Monitoring System (<http://106.37.208.233:20035/>), administered by China's Ministry of Ecology and Environment. The number of monitoring stations in a city ranges from 1 to 17, with a median of 4. These fixed-site stations are mandated not to be situated in the neighborhood of distinct emission sources (including but not limited to traffic, industry, and open burning). All measurement procedures are in accordance with China's Ambient Air Quality Standards (GB3095-2012). For each city, we derived daily 24-hour average concentrations of PM~2.5~, SO~2~, NO~2~, and CO and maximum 8-hour average concentrations of O~3~, averaged across all valid monitoring sites, to represent the population exposure to ambient air pollution. We also collected daily mean temperature and mean relative humidity for each city from the China Meteorological Data Sharing Service System (<http://data.cma.cn/>). During the study period, the missing data rates were 1.69% for PM~2.5~, 1.72% for O~3~, 1.68% for SO~2~, 1.67% for NO~2~, 1.72% for CO, 0.70% for temperature, and 0.70% for relative humidity. Days with missing monitoring measurements were excluded from analysis.

Statistical analysis {#sec010}
--------------------

We applied a 2-stage analytic approach to assess the associations between short-term exposure to air pollutants and daily hospital admissions; this approach has been widely used in previous multisite time-series studies \[[@pmed.1003188.ref001],[@pmed.1003188.ref029]--[@pmed.1003188.ref033]\]. The methods and models used in this study were determined before the analyses were conducted. In the first stage, we fit quasi-Poisson regression models separately to the daily time-series data of air pollutants and hospital admissions in each city for each cause, linked by date, to estimate the city- and cause-specific relative risk (RR) of hospital admission associated with air pollutants. The potential confounding effects of weather, seasonality, and long-term patterns were controlled for by smoothing functions (natural cubic splines). Specifically, we introduced the following covariates in the models, which were prespecified according to previously published studies \[[@pmed.1003188.ref001],[@pmed.1003188.ref019],[@pmed.1003188.ref020],[@pmed.1003188.ref029]--[@pmed.1003188.ref038]\]: (1) a natural cubic spline smoother of calendar day with 10 degrees of freedom (*df*) per year; (2) natural cubic spline smoothers of the temperature on the same day as admission (lag 0) and the average temperature over the 3 days before admission (lag 1--3), both with 6 *df*; (3) natural cubic spline smoothers of the relative humidity at lag 0 and lag 1--3, both with 3 *df*; (4) indicator variables for the day of the week and public holidays. The *df* values for calendar day, temperature, and relative humidity were selected based on the parameters used in previously published studies \[[@pmed.1003188.ref001],[@pmed.1003188.ref019],[@pmed.1003188.ref020],[@pmed.1003188.ref029]--[@pmed.1003188.ref038]\], and were further examined by sensitivity analyses described below. In the second stage, the city-specific RR estimates were pooled by random-effects meta-analyses to generate the national average RR estimates and *P* values testing the null hypothesis of no association \[[@pmed.1003188.ref036],[@pmed.1003188.ref039]\].

For PM~2.5~ and O~3~, we estimated their effects on daily hospital admissions using single-pollutant models and 2-pollutant models (adjusting for each other), as well as 3-pollutant models additionally adjusting for 1 of SO~2~, NO~2~, and CO to examine the robustness of our results. Multiple lag structures of PM~2.5~ and O~3~ (single-day and moving average exposures up to 3 days before admission) were used to explore the lag patterns in the acute effects of air pollution exposure. We always used the 2-day moving average exposure (lag 0--1) as the exposure metric of co-pollutants in 2- and 3-pollutant models \[[@pmed.1003188.ref032],[@pmed.1003188.ref033]\]. To address the multiple testing problem, we applied the Benjamini--Hochberg procedure to adjust the *P* values \[[@pmed.1003188.ref040]\]. Specifically, given a pollutant and a model specification (including the lag of exposure, adjustment for co-pollutants, and *df* for smoothing functions), we could derive 14 and 188 *P* values for major and minor disease categories, respectively. The 14 or 188 *P* values were treated as a batch and adjusted together through the Benjamini--Hochberg procedure. The associations with adjusted *P* \< 0.05 were considered statistically significant, keeping the false discovery rate \< 5%.

To explore potential effect modifiers, we conducted subgroup analyses by sex (male and female), age (\<65, 65--74, and ≥75 years), season (cool season, from October to March; warm season, from April to September) \[[@pmed.1003188.ref003],[@pmed.1003188.ref004]\], and region (North China and South China, divided by the Huai River--Qinling Mountain line \[the 33th parallel of north latitude, in practice\]) ([S1 Fig](#pmed.1003188.s001){ref-type="supplementary-material"}) \[[@pmed.1003188.ref041]\]. The statistical significance of effect modification (difference in effect estimates between subgroups) was tested by a 2-sample *Z*-test \[[@pmed.1003188.ref003],[@pmed.1003188.ref004]\]. We did not adjust the *P* values for association or effect modification in the subgroup analyses due to the exploratory nature of these analyses. Following the suggestion of reviewers, we further divided China into 6 regions based on geography, climate, and culture (middle north, northeast, east, middle south, southwest, and northwest) ([S1 Fig](#pmed.1003188.s001){ref-type="supplementary-material"}), and repeated the main analyses in each region to obtain the regional average estimates. We developed the exposure--response curves of the relationship between air pollution and hospitalization at the national level as was done in previous studies \[[@pmed.1003188.ref042],[@pmed.1003188.ref043]\]. Briefly, we replaced the linear term for air pollutants in the first-stage regression model with a natural cubic spline smoother with 3 *df* (technically, the coefficient of log RR was replaced by 3 coefficients used to represent the spline, and the variance of the coefficient was replaced by a 3 × 3 variance--covariance matrix). We then conducted multivariate random-effects meta-analyses to generate the national average estimates of the exposure--response curves.

As sensitivity analyses, we changed the *df* for the smoothing function of calendar day over the range of 6 to 14 per year, for temperature over the range of 3 to 9, and for relative humidity over the range of 3 to 9. These ranges were chosen to be consistent with previous nationwide studies \[[@pmed.1003188.ref019],[@pmed.1003188.ref020],[@pmed.1003188.ref031],[@pmed.1003188.ref036]--[@pmed.1003188.ref038]\]; we specially tested if the associations remained after more aggressive adjustment for potential confounding effects of time trends and weather conditions (i.e., using more *df*). Following the suggestion of reviewers, we included 8 outcomes (the CCS categories birth trauma; joint disorders and dislocations, trauma-related; spinal cord injury; sprains and strains; poisoning by psychotropic agents; poisoning by other medications and drugs; rehabilitation care, fitting of prostheses, and adjustment of devices; and medical examination/evaluation) as negative controls \[[@pmed.1003188.ref044]\], for which no biological or clinical evidence supports an association with air pollution. We repeated the main analyses on these negative control outcomes to examine if our results were substantially biased owing to residual confounding.

Finally, to gauge the potential public health benefits of air pollution control measures, we calculated the annual reduction in hospital admissions (*H*) and hospitalization expenses (*E*) attributable to a 10-μg/m^3^ reduction in the daily PM~2.5~ level in China \[[@pmed.1003188.ref001],[@pmed.1003188.ref020],[@pmed.1003188.ref030],[@pmed.1003188.ref031],[@pmed.1003188.ref037]\]. *H* is defined as *H* = (exp(β × Δ*x*) − 1) × *N*, where β is the national average effect estimate (log RR) for a 1-μg/m^3^ change in PM~2.5~ from the main analyses, Δ*x* is 10 μg/m^3^, and *N* is the total number of hospital admissions in China in 2016, collected from China Health and Family Planning Statistical Yearbook 2017 ([S2 Table](#pmed.1003188.s016){ref-type="supplementary-material"}). *E* is defined as *E* = *c* × *H*, where *c* is the average cost for each hospitalization in China in 2016, collected from China Health and Family Planning Statistical Yearbook 2017 ([S2 Table](#pmed.1003188.s016){ref-type="supplementary-material"}). *H* and *E* were calculated for each cause and then added up to get an overall estimate.

Results are presented as point estimates and 95% confidence intervals (CIs) of the percentage increase in daily hospital admissions associated with a 10-μg/m^3^ increase in PM~2.5~ or O~3~. *P* values are always 2-sided. All analyses were done in R software version 3.4.4 (R Foundation for Statistical Computing), with package *mgcv* for fitting regression models and package *mvmeta* for conducting random-effects meta-analyses.

Results {#sec011}
=======

A total of 117,338,867 hospital admissions in 252 Chinese cities (107 cities in North China and 145 cities in South China) ([S1 Fig](#pmed.1003188.s001){ref-type="supplementary-material"}) from 2013 to 2017 were included in this study, collected from 1,001 class 3 hospitals covered by the HQMS (387 hospitals in North China and 614 hospitals in South China) ([S1 Table](#pmed.1003188.s015){ref-type="supplementary-material"}). The demographic characteristics of the health data are provided in [Table 1](#pmed.1003188.t001){ref-type="table"} and [S3 Table](#pmed.1003188.s017){ref-type="supplementary-material"}. Overall, 51.7% of the hospitalized cases were male, and 71.3% were aged \<65 years. The distributions of daily counts of citywide hospital admissions are provided in [Table 2](#pmed.1003188.t002){ref-type="table"}. On average per city, there were 273.3 hospital admissions per day for 14 major disease categories and 188 minor disease categories. The national average levels of ambient air pollutants were 50.6 μg/m^3^ for PM~2.5~, 87.2 μg/m^3^ for O~3~, 24.0 μg/m^3^ for SO~2~, 31.4 μg/m^3^ for NO~2~, and 1.1 mg/m^3^ for CO during the study period. More statistics of the environmental data (distributions of citywide annual-average levels and national average Pearson correlation coefficients) are provided in [S4](#pmed.1003188.s018){ref-type="supplementary-material"} and [S5](#pmed.1003188.s019){ref-type="supplementary-material"} Tables.

10.1371/journal.pmed.1003188.t001

###### Demographic characteristics of hospital admissions for 14 major disease categories in 252 Chinese cities, 2013--2017.

![](pmed.1003188.t001){#pmed.1003188.t001g}

  Characteristic            Nationwide          North               South
  ------------------------- ------------------- ------------------- -------------------
  **Total *n***             103,230,193         39,376,209          63,853,984
  **Sex, *n* (%)**                                                  
  Male                      54,034,143 (52.3)   20,416,992 (51.9)   33,617,151 (52.6)
  Female                    49,196,050 (47.7)   18,959,217 (48.1)   30,236,833 (47.4)
  **Age, years, *n* (%)**                                           
  \<65                      72,508,804 (70.2)   27,715,976 (70.4)   44,792,828 (70.1)
  65--74                    16,821,027 (16.3)   6,538,588 (16.6)    10,282,439 (16.1)
  ≥75                       13,900,362 (13.5)   5,121,645 (13.0)    8,778,717 (13.7)

Data presented here are based on the ICD-10 codes (primary discharge diagnosis codes) covered by the 14 major disease categories. There are additionally 14,108,674 hospital admissions with ICD-10 codes covered by the 188 minor disease categories but not by the 14 major disease categories, because the 2 levels of disease categories form an approximate but not strict hierarchical structure. The 2 regions of China (North and South) are divided by the Huai River--Qinling Mountain line. Demographic characteristics of cause-specific hospital admissions are provided in [S3 Table](#pmed.1003188.s017){ref-type="supplementary-material"}.

10.1371/journal.pmed.1003188.t002

###### Summary statistics of annual-average daily counts of citywide hospital admissions in 252 Chinese cities, 2013--2017.

![](pmed.1003188.t002){#pmed.1003188.t002g}

  Major disease category                                                                                Mean    Standard deviation   Minimum   Percentile   Maximum                           
  ----------------------------------------------------------------------------------------------------- ------- -------------------- --------- ------------ --------- ------- ------- ------- ---------
  All                                                                                                   273.3   412.4                1.7       51.2         86.8      141.4   262.0   649.8   2,909.7
  Certain infectious and parasitic diseases                                                             10.3    14.7                 0.0       1.5          3.1       5.8     10.9    22.5    141.2
  Neoplasms                                                                                             36.1    73.1                 0.0       3.1          6.5       13.7    30.7    84.5    712.3
  Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism   3.5     4.7                  0.0       0.5          1.0       2.0     3.6     7.3     29.6
  Endocrine, nutritional, and metabolic diseases                                                        11.6    16.8                 0.0       2.2          3.8       6.2     11.0    26.3    123.1
  Mental and behavioral disorders                                                                       3.4     6.0                  0.0       0.2          0.5       1.0     3.4     10.1    40.1
  Diseases of the nervous system                                                                        10.4    15.6                 0.1       1.4          3.1       5.5     10.3    24.9    115.5
  Diseases of the eye and adnexa                                                                        10.2    20.1                 0.0       0.8          1.9       4.0     8.7     25.5    184.0
  Diseases of the ear and mastoid process                                                               2.8     4.2                  0.0       0.3          0.8       1.5     2.7     6.9     31.7
  Diseases of the circulatory system                                                                    47.7    68.2                 0.0       9.5          16.0      27.1    49.3    103.4   515.6
  Diseases of the respiratory system                                                                    35.5    40.9                 0.2       7.5          13.8      22.6    41.5    72.9    324.7
  Diseases of the digestive system                                                                      31.9    40.7                 0.0       6.2          11.7      18.6    34.0    68.4    294.4
  Diseases of the skin and subcutaneous tissue                                                          3.0     5.0                  0.0       0.3          0.6       1.3     3.1     7.4     45.3
  Diseases of the musculoskeletal system and connective tissue                                          12.9    22.1                 0.0       1.6          2.8       5.9     12.8    30.6    192.5
  Diseases of the genitourinary system                                                                  21.6    34.6                 0.0       3.0          6.3       10.9    20.1    51.9    269.2

The hospital admissions are grouped into 14 major disease categories by primary discharge diagnosis codes, based on the chapter division of the ICD-10 diagnostic coding system.

Generally, the effect estimates for PM~2.5~ for most disease categories were largest on the same day (lag 0 days), and decreased sharply in the subsequent days ([S2 Fig](#pmed.1003188.s002){ref-type="supplementary-material"}; [S6](#pmed.1003188.s020){ref-type="supplementary-material"}--[S12](#pmed.1003188.s026){ref-type="supplementary-material"} Tables). The lag patterns of the effect estimates for O~3~ varied by disease category, with same-day exposure (lag 0 days) leading to the largest effect estimates for some diseases (e.g., diseases of the circulatory system) and previous-day exposure (lag 1 day) leading to the largest effect estimates for other diseases (e.g., diseases of the respiratory system) ([S3 Fig](#pmed.1003188.s003){ref-type="supplementary-material"}; [S13](#pmed.1003188.s027){ref-type="supplementary-material"}--[S19](#pmed.1003188.s033){ref-type="supplementary-material"} Tables). At the national level, the same-day concentration of PM~2.5~ (lag 0 days) was significantly positively associated with hospital admissions for 13 major disease categories in both single- and 2-pollutant models ([Fig 1](#pmed.1003188.g001){ref-type="fig"}). For example, each 10-μg/m^3^ increase in same-day PM~2.5~ was associated with a 0.21% (95% CI 0.15% to 0.27%; adjusted *P* \< 0.001) increase in hospital admissions for diseases of the digestive system when adjusted for O~3~. In particular, the associations of PM~2.5~ with 7 major disease categories were robust to the lag of exposure and further adjustment for co-pollutants ([S2](#pmed.1003188.s002){ref-type="supplementary-material"} and [S4](#pmed.1003188.s004){ref-type="supplementary-material"} Figs): (1) endocrine, nutritional, and metabolic diseases; (2) diseases of the nervous system; (3) diseases of the circulatory system; (4) diseases of the respiratory system; (5) diseases of the digestive system; (6) diseases of the musculoskeletal system and connective tissue; and (7) diseases of the genitourinary system. At the national level, the 2-day moving average concentration of O~3~ (lag 0--1 days) was significantly positively associated with hospital admissions for diseases of the respiratory system in both single- and 2-pollutant models, and the association was robust to the lag of exposure and further adjustment for co-pollutants ([Fig 1](#pmed.1003188.g001){ref-type="fig"}, [S3](#pmed.1003188.s003){ref-type="supplementary-material"} and [S5](#pmed.1003188.s005){ref-type="supplementary-material"} Figs).

![Percent change in hospital admissions per 10-μg/m^3^ increase in PM~2.5~ and O~3~ by major disease category, on average across all cities.\
Results are presented as point estimates and 95% CIs of the percentage increase in daily hospital admissions associated with a 10-μg/m^3^ increase in PM~2.5~ or O~3~. Major disease categories are based on the chapter division of the ICD-10 diagnostic coding system. Single-day exposure on the same day (lag 0) was used as the exposure metric of PM~2.5~. Two-day moving average exposure (lag 0--1) was used as the exposure metric of O~3~. In single-pollutant models, the effects of PM~2.5~ and O~3~ were estimated without adjustment for co-pollutants; in 2-pollutant models, the effects of PM~2.5~ were estimated after adjustment for O~3~, and the effects of O~3~ were estimated after adjustment for PM~2.5~. The Benjamini--Hochberg procedure was applied to adjust the *P* values across the 14 major disease categories. \*Statistically significant estimate (*P* \< 0.05).](pmed.1003188.g001){#pmed.1003188.g001}

The national average RR estimates for PM~2.5~ and O~3~ by minor disease category are shown in [Table 3](#pmed.1003188.t003){ref-type="table"} and [S6](#pmed.1003188.s020){ref-type="supplementary-material"}--[S19](#pmed.1003188.s033){ref-type="supplementary-material"} Tables. The same-day concentration of PM~2.5~ (lag 0 days) was significantly positively associated with hospital admissions for 35 minor disease categories in both single- and 2-pollutant models, 6 categories in single-pollutant models only, and 4 categories in 2-pollutant models only. Among the 35 minor disease categories significantly associated with PM~2.5~ in both single- and 2-pollutant models, there were 9 categories of circulatory diseases including essential hypertension, acute myocardial infarction, ischemic heart diseases, pulmonary heart disease, cardiac dysrhythmias, congestive heart failure, acute cerebrovascular disease, and transient cerebral ischemia; 6 categories of respiratory diseases, including pneumonia, acute bronchitis, upper respiratory infections, and chronic obstructive pulmonary disease (COPD) and bronchiectasis; 7 categories of digestive diseases, including intestinal infection, esophageal disorders, gastritis and duodenitis, appendiceal conditions, liver diseases, gastrointestinal hemorrhage, and noninfectious gastroenteritis; 3 categories of genitourinary diseases, including chronic renal failure, calculus of urinary tract, and nephritis, nephrosis, and renal sclerosis; and 10 categories of other diseases, including bacterial infection, cancer of bronchus and lung, cancer of breast, diabetes mellitus without/with complications, crystal arthropathies, anemia, Parkinson disease, chronic ulcer of skin, and spondylosis, intervertebral disc disorders, and other back problems. For example, each 10-μg/m^3^ increase in same-day PM~2.5~ was associated with a 0.34% (95% CI 0.14% to 0.53%; adjusted *P* = 0.007) increase in hospital admissions for gastrointestinal hemorrhage when adjusted for O~3~. The 2-day moving average concentration of O~3~ (lag 0--1 days) was significantly positively associated with hospital admissions for pneumonia, upper respiratory infections, and asthma in both single- and 2-pollutant models, as well as acute bronchitis, COPD and bronchiectasis, and other upper respiratory disease in single-pollutant models only.

10.1371/journal.pmed.1003188.t003

###### Percent change in hospital admissions per 10-μg/m^3^ increase in PM~2.5~ and O~3~ by minor disease category, on average across all cities.

![](pmed.1003188.t003){#pmed.1003188.t003g}

  CCS code   Minor disease category                                                                                               Percent change in admissions per 10-μg/m^3^ increase in PM~2.5~   Percent change in admissions per 10-μg/m^3^ increase in O~3~                                                                                                                                                                      
  ---------- -------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------- -------------------------------------------------------------- ---------------------- ---------------------------------------------- ---------------------- ---------------------------------------------- ---------------------- ----------------------------------------------
  3          Bacterial infection, unspecified site                                                                                0.87 (0.44, 1.29)                                                 \<0.001[\*](#t003fn002){ref-type="table-fn"}                   0.93 (0.40, 1.46)      0.006[\*](#t003fn002){ref-type="table-fn"}     −0.06 (−0.59, 0.46)    0.919                                          −0.22 (−0.81, 0.38)    0.877
  13         Cancer of stomach                                                                                                    0.18 (0.03, 0.33)                                                 0.077                                                          0.24 (0.07, 0.42)      0.038[\*](#t003fn002){ref-type="table-fn"}     0.09 (−0.12, 0.30)     0.842                                          0.06 (−0.16, 0.29)     0.920
  19         Cancer of bronchus, lung                                                                                             0.27 (0.15, 0.40)                                                 \<0.001[\*](#t003fn002){ref-type="table-fn"}                   0.29 (0.16, 0.42)      \<0.001[\*](#t003fn002){ref-type="table-fn"}   0.07 (−0.07, 0.20)     0.784                                          0.07 (−0.07, 0.22)     0.814
  24         Cancer of breast                                                                                                     0.34 (0.19, 0.48)                                                 \<0.001[\*](#t003fn002){ref-type="table-fn"}                   0.37 (0.19, 0.54)      \<0.001[\*](#t003fn002){ref-type="table-fn"}   0.08 (−0.10, 0.26)     0.839                                          0.05 (−0.14, 0.24)     0.920
  45         Maintenance chemotherapy; radiotherapy                                                                               0.10 (0.02, 0.18)                                                 0.068                                                          0.11 (0.03, 0.18)      0.030[\*](#t003fn002){ref-type="table-fn"}     −0.06 (−0.14, 0.02)    0.626                                          −0.07 (−0.15, 0.02)    0.707
  49         Diabetes mellitus without complication                                                                               0.23 (0.11, 0.35)                                                 0.002[\*](#t003fn002){ref-type="table-fn"}                     0.27 (0.13, 0.41)      0.001[\*](#t003fn002){ref-type="table-fn"}     0.10 (−0.04, 0.25)     0.674                                          0.04 (−0.12, 0.20)     0.931
  50         Diabetes mellitus with complications                                                                                 0.30 (0.18, 0.41)                                                 \<0.001[\*](#t003fn002){ref-type="table-fn"}                   0.35 (0.21, 0.49)      \<0.001[\*](#t003fn002){ref-type="table-fn"}   0.20 (0.04, 0.35)      0.164                                          0.10 (−0.07, 0.27)     0.808
  54         Gout and other crystal arthropathies                                                                                 0.53 (0.16, 0.90)                                                 0.027[\*](#t003fn002){ref-type="table-fn"}                     0.71 (0.23, 1.18)      0.024[\*](#t003fn002){ref-type="table-fn"}     0.06 (−0.33, 0.44)     0.919                                          −0.06 (−0.48, 0.36)    0.943
  59         Deficiency and other anemia                                                                                          0.29 (0.11, 0.47)                                                 0.012[\*](#t003fn002){ref-type="table-fn"}                     0.37 (0.16, 0.59)      0.006[\*](#t003fn002){ref-type="table-fn"}     −0.05 (−0.25, 0.16)    0.919                                          −0.09 (−0.31, 0.13)    0.814
  72         Anxiety, somatoform, dissociative, and personality disorders                                                         0.29 (0.07, 0.52)                                                 0.049[\*](#t003fn002){ref-type="table-fn"}                     0.31 (0.05, 0.58)      0.080                                          0.23 (−0.02, 0.47)     0.554                                          0.21 (−0.06, 0.47)     0.707
  79         Parkinson disease                                                                                                    0.50 (0.12, 0.88)                                                 0.047[\*](#t003fn002){ref-type="table-fn"}                     0.57 (0.14, 1.00)      0.049[\*](#t003fn002){ref-type="table-fn"}     −0.02 (−0.46, 0.42)    0.963                                          −0.14 (−0.56, 0.28)    0.890
  93         Conditions associated with dizziness or vertigo                                                                      0.34 (0.15, 0.53)                                                 0.003[\*](#t003fn002){ref-type="table-fn"}                     0.27 (0.05, 0.49)      0.067                                          −0.00 (−0.22, 0.22)    0.992                                          −0.08 (−0.32, 0.15)    0.877
  97         Peri-, endo-, and myocarditis; cardiomyopathy (except that caused by tuberculosis or sexually transmitted disease)   0.28 (0.08, 0.48)                                                 0.036[\*](#t003fn002){ref-type="table-fn"}                     0.30 (0.06, 0.54)      0.068                                          0.09 (−0.14, 0.32)     0.888                                          0.03 (−0.22, 0.27)     0.958
  98         Essential hypertension                                                                                               0.22 (0.10, 0.34)                                                 0.003[\*](#t003fn002){ref-type="table-fn"}                     0.29 (0.14, 0.44)      0.001[\*](#t003fn002){ref-type="table-fn"}     −0.18 (−0.31, −0.05)   0.114                                          −0.24 (−0.38, −0.10)   0.035[\*](#t003fn002){ref-type="table-fn"}
  100        Acute myocardial infarction                                                                                          0.38 (0.24, 0.52)                                                 \<0.001[\*](#t003fn002){ref-type="table-fn"}                   0.35 (0.18, 0.52)      \<0.001[\*](#t003fn002){ref-type="table-fn"}   0.20 (0.03, 0.38)      0.243                                          0.15 (−0.04, 0.34)     0.707
  101        Coronary atherosclerosis and other heart disease                                                                     0.30 (0.22, 0.37)                                                 \<0.001[\*](#t003fn002){ref-type="table-fn"}                   0.29 (0.21, 0.37)      \<0.001[\*](#t003fn002){ref-type="table-fn"}   0.14 (0.04, 0.24)      0.102                                          0.06 (−0.04, 0.17)     0.790
  103        Pulmonary heart disease                                                                                              0.58 (0.27, 0.89)                                                 0.002[\*](#t003fn002){ref-type="table-fn"}                     0.53 (0.17, 0.89)      0.024[\*](#t003fn002){ref-type="table-fn"}     0.31 (−0.09, 0.70)     0.636                                          0.18 (−0.23, 0.59)     0.814
  106        Cardiac dysrhythmias                                                                                                 0.30 (0.16, 0.44)                                                 \<0.001[\*](#t003fn002){ref-type="table-fn"}                   0.28 (0.13, 0.43)      0.002[\*](#t003fn002){ref-type="table-fn"}     0.21 (0.06, 0.36)      0.114                                          0.21 (0.05, 0.38)      0.277
  108        Congestive heart failure, nonhypertensive                                                                            0.45 (0.24, 0.67)                                                 \<0.001[\*](#t003fn002){ref-type="table-fn"}                   0.42 (0.18, 0.67)      0.007[\*](#t003fn002){ref-type="table-fn"}     0.06 (−0.20, 0.32)     0.919                                          −0.11 (−0.39, 0.16)    0.814
  109        Acute cerebrovascular disease                                                                                        0.16 (0.09, 0.23)                                                 \<0.001[\*](#t003fn002){ref-type="table-fn"}                   0.20 (0.12, 0.28)      \<0.001[\*](#t003fn002){ref-type="table-fn"}   −0.02 (−0.11, 0.08)    0.919                                          −0.05 (−0.15, 0.05)    0.814
  111        Other and ill-defined cerebrovascular disease                                                                        0.24 (0.08, 0.39)                                                 0.017[\*](#t003fn002){ref-type="table-fn"}                     0.30 (0.12, 0.48)      0.008[\*](#t003fn002){ref-type="table-fn"}     −0.13 (−0.31, 0.05)    0.681                                          −0.13 (−0.32, 0.07)    0.759
  112        Transient cerebral ischemia                                                                                          0.26 (0.14, 0.38)                                                 \<0.001[\*](#t003fn002){ref-type="table-fn"}                   0.33 (0.19, 0.47)      \<0.001[\*](#t003fn002){ref-type="table-fn"}   −0.00 (−0.15, 0.14)    0.986                                          −0.07 (−0.22, 0.09)    0.814
  113        Late effects of cerebrovascular disease                                                                              0.32 (0.08, 0.57)                                                 0.049[\*](#t003fn002){ref-type="table-fn"}                     0.33 (0.03, 0.63)      0.098                                          0.06 (−0.21, 0.32)     0.919                                          −0.04 (−0.32, 0.25)    0.943
  122        Pneumonia (except that caused by tuberculosis or sexually transmitted disease)                                       0.36 (0.28, 0.44)                                                 \<0.001[\*](#t003fn002){ref-type="table-fn"}                   0.28 (0.19, 0.37)      \<0.001[\*](#t003fn002){ref-type="table-fn"}   0.29 (0.19, 0.39)      \<0.001[\*](#t003fn002){ref-type="table-fn"}   0.21 (0.10, 0.32)      0.007[\*](#t003fn002){ref-type="table-fn"}
  125        Acute bronchitis                                                                                                     0.32 (0.18, 0.46)                                                 \<0.001[\*](#t003fn002){ref-type="table-fn"}                   0.32 (0.16, 0.48)      0.001[\*](#t003fn002){ref-type="table-fn"}     0.30 (0.14, 0.46)      0.010[\*](#t003fn002){ref-type="table-fn"}     0.19 (0.02, 0.36)      0.370
  126        Other upper respiratory infections                                                                                   0.31 (0.17, 0.44)                                                 \<0.001[\*](#t003fn002){ref-type="table-fn"}                   0.28 (0.13, 0.44)      0.004[\*](#t003fn002){ref-type="table-fn"}     0.43 (0.28, 0.58)      \<0.001[\*](#t003fn002){ref-type="table-fn"}   0.44 (0.28, 0.59)      \<0.001[\*](#t003fn002){ref-type="table-fn"}
  127        Chronic obstructive pulmonary disease and bronchiectasis                                                             0.52 (0.40, 0.64)                                                 \<0.001[\*](#t003fn002){ref-type="table-fn"}                   0.51 (0.38, 0.64)      \<0.001[\*](#t003fn002){ref-type="table-fn"}   0.28 (0.14, 0.42)      0.002[\*](#t003fn002){ref-type="table-fn"}     0.10 (−0.04, 0.24)     0.718
  128        Asthma                                                                                                               −0.11 (−0.39, 0.16)                                               0.630                                                          −0.39 (−0.71, −0.07)   0.073                                          0.72 (0.39, 1.04)      \<0.001[\*](#t003fn002){ref-type="table-fn"}   0.75 (0.43, 1.08)      \<0.001[\*](#t003fn002){ref-type="table-fn"}
  133        Other lower respiratory disease                                                                                      0.28 (0.17, 0.39)                                                 \<0.001[\*](#t003fn002){ref-type="table-fn"}                   0.30 (0.17, 0.43)      \<0.001[\*](#t003fn002){ref-type="table-fn"}   0.06 (−0.07, 0.19)     0.799                                          −0.06 (−0.19, 0.08)    0.816
  134        Other upper respiratory disease                                                                                      0.31 (0.17, 0.45)                                                 \<0.001[\*](#t003fn002){ref-type="table-fn"}                   0.25 (0.09, 0.42)      0.019[\*](#t003fn002){ref-type="table-fn"}     0.29 (0.13, 0.45)      0.014[\*](#t003fn002){ref-type="table-fn"}     0.21 (0.04, 0.39)      0.310
  135        Intestinal infection                                                                                                 0.76 (0.40, 1.12)                                                 \<0.001[\*](#t003fn002){ref-type="table-fn"}                   0.97 (0.59, 1.35)      \<0.001[\*](#t003fn002){ref-type="table-fn"}   0.10 (−0.23, 0.44)     0.919                                          −0.22 (−0.59, 0.14)    0.790
  138        Esophageal disorders                                                                                                 0.34 (0.10, 0.59)                                                 0.031[\*](#t003fn002){ref-type="table-fn"}                     0.39 (0.11, 0.67)      0.038[\*](#t003fn002){ref-type="table-fn"}     0.04 (−0.31, 0.39)     0.919                                          −0.11 (−0.48, 0.26)    0.904
  140        Gastritis and duodenitis                                                                                             0.24 (0.08, 0.40)                                                 0.018[\*](#t003fn002){ref-type="table-fn"}                     0.24 (0.06, 0.42)      0.049[\*](#t003fn002){ref-type="table-fn"}     0.00 (−0.16, 0.16)     0.990                                          −0.07 (−0.26, 0.12)    0.877
  142        Appendicitis and other appendiceal conditions                                                                        0.26 (0.12, 0.41)                                                 0.003[\*](#t003fn002){ref-type="table-fn"}                     0.25 (0.08, 0.42)      0.024[\*](#t003fn002){ref-type="table-fn"}     0.02 (−0.14, 0.19)     0.919                                          −0.03 (−0.20, 0.15)    0.943
  148        Peritonitis and intestinal abscess                                                                                   0.57 (0.13, 1.00)                                                 0.049[\*](#t003fn002){ref-type="table-fn"}                     0.40 (−0.10, 0.91)     0.293                                          0.29 (−0.24, 0.82)     0.759                                          0.20 (−0.35, 0.76)     0.877
  149        Biliary tract disease                                                                                                0.07 (−0.03, 0.17)                                                0.348                                                          0.16 (0.04, 0.27)      0.033[\*](#t003fn002){ref-type="table-fn"}     −0.03 (−0.16, 0.10)    0.919                                          −0.03 (−0.16, 0.11)    0.943
  151        Other liver diseases                                                                                                 0.25 (0.12, 0.38)                                                 0.001[\*](#t003fn002){ref-type="table-fn"}                     0.22 (0.08, 0.37)      0.019[\*](#t003fn002){ref-type="table-fn"}     0.22 (0.07, 0.36)      0.077                                          0.14 (−0.01, 0.30)     0.630
  153        Gastrointestinal hemorrhage                                                                                          0.30 (0.14, 0.46)                                                 0.002[\*](#t003fn002){ref-type="table-fn"}                     0.34 (0.14, 0.53)      0.007[\*](#t003fn002){ref-type="table-fn"}     0.11 (−0.08, 0.29)     0.745                                          0.00 (−0.21, 0.21)     1.000
  154        Noninfectious gastroenteritis                                                                                        0.44 (0.23, 0.64)                                                 \<0.001[\*](#t003fn002){ref-type="table-fn"}                   0.43 (0.21, 0.64)      0.001[\*](#t003fn002){ref-type="table-fn"}     0.29 (0.08, 0.50)      0.114                                          0.18 (−0.06, 0.42)     0.707
  156        Nephritis, nephrosis, and renal sclerosis                                                                            0.23 (0.08, 0.39)                                                 0.020[\*](#t003fn002){ref-type="table-fn"}                     0.28 (0.09, 0.46)      0.024[\*](#t003fn002){ref-type="table-fn"}     0.16 (−0.02, 0.34)     0.568                                          0.16 (−0.04, 0.35)     0.707
  158        Chronic renal failure                                                                                                0.32 (0.19, 0.45)                                                 \<0.001[\*](#t003fn002){ref-type="table-fn"}                   0.32 (0.17, 0.47)      \<0.001[\*](#t003fn002){ref-type="table-fn"}   −0.02 (−0.18, 0.14)    0.919                                          −0.10 (−0.26, 0.07)    0.808
  160        Calculus of urinary tract                                                                                            0.29 (0.13, 0.45)                                                 0.003[\*](#t003fn002){ref-type="table-fn"}                     0.30 (0.10, 0.49)      0.019[\*](#t003fn002){ref-type="table-fn"}     0.21 (0.03, 0.38)      0.207                                          0.17 (−0.02, 0.35)     0.646
  161        Other diseases of kidney and ureters                                                                                 0.22 (0.06, 0.38)                                                 0.035[\*](#t003fn002){ref-type="table-fn"}                     0.19 (−0.00, 0.37)     0.171                                          0.25 (0.08, 0.42)      0.102                                          0.23 (0.04, 0.41)      0.357
  199        Chronic ulcer of skin                                                                                                0.91 (0.33, 1.48)                                                 0.013[\*](#t003fn002){ref-type="table-fn"}                     0.99 (0.31, 1.68)      0.025[\*](#t003fn002){ref-type="table-fn"}     0.32 (−0.33, 0.97)     0.784                                          0.02 (−0.66, 0.70)     0.996
  205        Spondylosis, intervertebral disc disorders, and other back problems                                                  0.27 (0.14, 0.40)                                                 \<0.001[\*](#t003fn002){ref-type="table-fn"}                   0.33 (0.19, 0.47)      \<0.001[\*](#t003fn002){ref-type="table-fn"}   0.07 (−0.06, 0.19)     0.749                                          0.03 (−0.11, 0.17)     0.943
  212        Other bone disease and musculoskeletal deformities                                                                   0.27 (−0.05, 0.58)                                                0.238                                                          0.51 (0.14, 0.89)      0.038[\*](#t003fn002){ref-type="table-fn"}     −0.15 (−0.54, 0.25)    0.890                                          −0.18 (−0.59, 0.24)    0.814

Results are presented as point estimates and 95% CIs of the percentage increase in daily hospital admissions associated with a 10-μg/m^3^ increase in PM~2.5~ or O~3~. Minor disease categories are based on the Clinical Classifications Software (CCS). Single-day exposure on the same day (lag 0) was used as the exposure metric of PM~2.5~. Two-day moving average exposure (lag 0--1) was used as the exposure metric of O~3~. In single-pollutant models, the effects of PM~2.5~ and O~3~ were estimated without adjustment for co-pollutants; in 2-pollutant models, the effects of PM~2.5~ were estimated after adjustment for O~3~, and the effects of O~3~ were estimated after adjustment for PM~2.5~. The Benjamini--Hochberg procedure was applied to adjust the *P* values across the 188 minor disease categories. The 46 minor disease categories significantly associated with PM~2.5~ or O~3~ in single- or 2-pollutant models after multiple comparisons adjustment are listed here; results for all disease categories are shown in [S6](#pmed.1003188.s020){ref-type="supplementary-material"}--[S19](#pmed.1003188.s033){ref-type="supplementary-material"} Tables.

\*Statistically significant estimate (*P* \< 0.05).

The results of the subgroup analyses are shown in [Fig 2](#pmed.1003188.g002){ref-type="fig"}, [S6](#pmed.1003188.s006){ref-type="supplementary-material"} and [S7](#pmed.1003188.s007){ref-type="supplementary-material"} Figs. We found stronger associations between PM~2.5~ and most disease categories in people aged 65--74 years or ≥75 years than in people aged \<65 years; for several disease categories, the effect modification was statistically significant (in an exploratory analysis without adjustment for multiple comparisons) ([Fig 2](#pmed.1003188.g002){ref-type="fig"} and [S6 Fig](#pmed.1003188.s006){ref-type="supplementary-material"}). However, we did not observe the same pattern for O~3~ ([S7 Fig](#pmed.1003188.s007){ref-type="supplementary-material"}). The evidence of effect modification by sex, season, and region (using both 2- and 6-region divisions) was mixed and uncertain ([S6](#pmed.1003188.s006){ref-type="supplementary-material"}, [S7](#pmed.1003188.s007){ref-type="supplementary-material"}, [S12](#pmed.1003188.s012){ref-type="supplementary-material"} and [S13](#pmed.1003188.s013){ref-type="supplementary-material"} Figs). The results of the exposure--response analyses are shown in [Fig 3](#pmed.1003188.g003){ref-type="fig"}, [S8](#pmed.1003188.s008){ref-type="supplementary-material"} and [S9](#pmed.1003188.s009){ref-type="supplementary-material"} Figs. The exposure--response curves between PM~2.5~ and hospital admissions generally showed steeper slopes at lower concentrations than at higher concentrations, with no safety threshold below which PM~2.5~ exposure had no health effect ([Fig 3](#pmed.1003188.g003){ref-type="fig"} and [S8 Fig](#pmed.1003188.s008){ref-type="supplementary-material"}). A threshold of O~3~ in the range of 40 to 50 μg/m^3^ (near the background level of O~3~) was observed in the exposure--response curve between O~3~ and hospital admissions for diseases of the respiratory system ([S9 Fig](#pmed.1003188.s009){ref-type="supplementary-material"}).

![Percent change in hospital admissions per 10-μg/m^3^ increase in PM~2.5~ by major disease category for study subgroups, on average across all cities.\
(A) Endocrine, nutritional, and metabolic diseases; (B) nervous diseases; (C) circulatory diseases; (D) respiratory diseases; (E) digestive diseases; (F) genitourinary diseases. Results are presented as point estimates and 95% CIs of the percentage increase in daily hospital admissions associated with a 10-μg/m^3^ increase in PM~2.5~. Major disease categories are based on the chapter division of the ICD-10 diagnostic coding system. Single-day exposure on the same day (lag 0) was used as the exposure metric of PM~2.5~. The effects of PM~2.5~ were estimated after adjustment for O~3~. The cool season is from October to March; the warm season is from April to September. The 2 regions of China (North and South) are divided by the Huai River--Qinling Mountain line. The *P* values were not adjusted for multiple comparisons. Results for all disease categories and for O~3~ are shown in [S6](#pmed.1003188.s006){ref-type="supplementary-material"} and [S7](#pmed.1003188.s007){ref-type="supplementary-material"} Figs. \*Statistically significant estimate (*P* \< 0.05).](pmed.1003188.g002){#pmed.1003188.g002}

![Exposure--response curves of the effects of PM~2.5~ on hospital admissions by major disease category, on average across all cities.\
(A) Endocrine, nutritional, and metabolic diseases; (B) nervous diseases; (C) circulatory diseases; (D) respiratory diseases; (E) digestive diseases; (F) genitourinary diseases. The vertical scale represents the relative change from the mean effect of PM~2.5~ on daily hospital admissions, with solid lines indicating point estimates and dashed lines indicating 95% CIs. Major disease categories are based on the chapter division of the ICD-10 diagnostic coding system. Single-day exposure on the same day (lag 0) was used as the exposure metric of PM~2.5~. The national average exposure--response curves were developed using multivariate meta-analysis approaches. Results for all disease categories and for O~3~ are shown in [S8](#pmed.1003188.s008){ref-type="supplementary-material"} and [S9](#pmed.1003188.s009){ref-type="supplementary-material"} Figs.](pmed.1003188.g003){#pmed.1003188.g003}

The results of the sensitivity analyses are shown in [S10](#pmed.1003188.s010){ref-type="supplementary-material"} and [S11](#pmed.1003188.s011){ref-type="supplementary-material"} Figs. Our results remained stable using alternative *df* for the smoothing functions of temperature and relative humidity. The results for PM~2.5~ remained stable using alternative *df* for the smoothing function of calendar day. The results for O~3~ were substantially biased when using too few *df* for the smoothing function of calendar day (e.g., the association between O~3~ and hospital admissions for diseases of the respiratory system even became negative when *df* = 6 per year), indicating that the confounding effects of seasonality and/or long-term patterns were not controlled adequately in that case; however, the bias disappeared with *df* ≥ 8 per year, and the results remained stable with increasing *df* up to 14 per year, demonstrating that the models used in the main analyses had successfully removed the confounding effects. None of the 8 negative control outcomes were associated with PM~2.5~ or O~3~ in single- or 2-pollutant models, which provided further reassurance that our findings were not substantially confounded or biased ([S20 Table](#pmed.1003188.s034){ref-type="supplementary-material"}).

[Table 4](#pmed.1003188.t004){ref-type="table"} provides the estimated annual reduction in cause-specific hospital admissions and hospitalization expenses attributable to a 10-μg/m^3^ reduction in daily PM~2.5~ level in China. Based on hospital admissions and costs in 2016, a 10-μg/m^3^ reduction in PM~2.5~ would reduce the number of hospital admissions by 120,145 (95% CI 107,698 to 132,592) and hospitalization expenses by 1,011.9 (95% CI 903.4 to 1,120.4) million yuan nationwide, of which 52.4% of reduced cases and 50.1% of reduced costs would be attributable to reductions in diseases of the circulatory and respiratory systems, with reductions in non-cardiorespiratory diseases accounting for the other 47.6% of reduced cases and 49.9% of reduced costs.

10.1371/journal.pmed.1003188.t004

###### Annual reduction in hospital admissions and hospitalization expenses attributable to a 10-μg/m^3^ reduction in daily PM~2.5~ level in China.

![](pmed.1003188.t004){#pmed.1003188.t004g}

  Major disease category                                                                                Annual reduction in hospital admissions (95% CI)   Annual reduction in hospitalization expenses, million ¥ (95% CI)
  ----------------------------------------------------------------------------------------------------- -------------------------------------------------- ------------------------------------------------------------------
  All                                                                                                   120,145 (107,698 to 132,592)                       1,011.9 (903.4 to 1,120.4)
  Certain infectious and parasitic diseases                                                             3,616 (746 to 6,487)                               20.0 (4.1 to 35.8)
  Neoplasms                                                                                             6,948 (3,961 to 9,936)                             107.2 (61.1 to 153.3)
  Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism   1,230 (369 to 2,090)                               8.3 (2.5 to 14.1)
  Endocrine, nutritional, and metabolic diseases                                                        5,405 (3,467 to 7,343)                             43.3 (27.8 to 58.8)
  Mental and behavioral disorders                                                                       950 (257 to 1,644)                                 6.6 (1.8 to 11.5)
  Diseases of the nervous system                                                                        4,727 (2,581 to 6,872)                             35.3 (19.3 to 51.3)
  Diseases of the eye and adnexa                                                                        1,832 (-817 to 4,480)                              10.9 (-4.9 to 26.7)
  Diseases of the ear and mastoid process                                                               1,242 (227 to 2,256)                               7.1 (1.3 to 12.9)
  Diseases of the circulatory system                                                                    32,968 (26,343 to 39,594)                          337.0 (269.3 to 404.7)
  Diseases of the respiratory system                                                                    30,030 (23,855 to 36,205)                          170.2 (135.2 to 205.1)
  Diseases of the digestive system                                                                      16,110 (11,297 to 20,924)                          131.8 (92.4 to 171.2)
  Diseases of the skin and subcutaneous tissue                                                          1,412 (459 to 2,364)                               8.4 (2.7 to 14.0)
  Diseases of the musculoskeletal system and connective tissue                                          6,109 (3,791 to 8,428)                             64.0 (39.7 to 88.2)
  Diseases of the genitourinary system                                                                  7,566 (4,625 to 10,508)                            61.8 (37.8 to 85.8)

The estimation was based on the total number of hospital admissions and the average cost for each hospitalization in China in 2016, collected from China Health and Family Planning Statistical Yearbook 2017. ¥ = Chinese yuan.

Discussion {#sec012}
==========

This national study systematically assessed the acute effects of main air pollutants on hospital admissions for 14 major and 188 minor disease categories using standardized analytic approaches, providing a unified perspective on the health effects of air pollution on multiple organ systems, with minimal publication bias. We found robust positive associations between PM~2.5~ and 7 major disease categories and between O~3~ and respiratory diseases, as well as significant evidence that diseases in dozens of minor disease categories---many are non-cardiorespiratory diseases---can be triggered and/or exacerbated by short-term exposure to air pollution. Consistent with prior research \[[@pmed.1003188.ref004],[@pmed.1003188.ref020],[@pmed.1003188.ref031],[@pmed.1003188.ref036],[@pmed.1003188.ref037]\], we generally observed higher risks related to PM~2.5~ in older people (65--74 or ≥75 years) than in younger people (\<65 years), and steeper slopes of exposure--response curves between PM~2.5~ and hospital admissions at lower concentrations than at higher concentrations.

Our results regarding cardiorespiratory diseases are in line with the current understanding of the deleterious impacts of air pollution on the circulatory and respiratory systems. The well-known outcomes associated with air pollutants serve as positive controls for this study. The size of effects in this analysis is generally similar to those of recent multisite studies in China \[[@pmed.1003188.ref020],[@pmed.1003188.ref031],[@pmed.1003188.ref036],[@pmed.1003188.ref037]\], and smaller than those from North America and Europe \[[@pmed.1003188.ref001],[@pmed.1003188.ref002],[@pmed.1003188.ref004]\]. The lower effect estimates of this study than those from high-income countries may have at least 2 possible explanations. First, the levels of particulate air pollution were much higher in China than in the high-income countries. As observed in our study and previous multisite studies \[[@pmed.1003188.ref004],[@pmed.1003188.ref020],[@pmed.1003188.ref031],[@pmed.1003188.ref037]\], the slopes of exposure--response relationships were generally steeper at lower concentrations than at higher concentrations, which may be partly attributable to larger exposure measurement errors on heavily polluted days, when public health interventions would be reinforced and people would more actively take self-protection measures. Second, the chemical profile of PM~2.5~ was different between China and the high-income countries. PM~2.5~ in China's air had a higher proportion of crustal materials, which may have lower toxicity than components that originate from fossil fuel combustion \[[@pmed.1003188.ref031],[@pmed.1003188.ref037]\]. We demonstrated that ambient exposure to PM~2.5~ was robustly associated with hospital admissions for endocrine, nutritional, and metabolic diseases and diseases of the nervous system in the Chinese population. We also identified diabetes mellitus without/with complications and Parkinson disease as typical minor disease categories that were significantly associated with same-day PM~2.5~ in both single- and 2-pollutant models. These results support the growing evidence that acute exposure to air pollution can increase the risk of certain diseases of these organ systems \[[@pmed.1003188.ref045]--[@pmed.1003188.ref047]\].

More importantly, by inspecting the associations of air pollution with a broad spectrum of diseases, this study provides new insights into the health effects of air pollution that were scarcely or never reported before. We found a robust positive association between PM~2.5~ and hospitalizations for diseases of the digestive system. Previous studies have suggested that air pollution exposure is associated with the risk of some gastrointestinal diseases, e.g., gastroenteric disorders in young children \[[@pmed.1003188.ref048]\], acute appendicitis \[[@pmed.1003188.ref049]\], inflammatory bowel diseases \[[@pmed.1003188.ref050]\], and peptic ulcer bleeding \[[@pmed.1003188.ref010]\]. For example, Tian et al. \[[@pmed.1003188.ref010]\] reported a positive association of daily air pollution and emergency admissions for peptic ulcer bleeding using the data of 8,566 recorded cases in Hong Kong's elderly population during 2005--2010, which was one of the largest studies to date on this topic. Exposure to PM~2.5~ was found to induce a nonalcoholic steatohepatitis-like phenotype and hepatic fibrosis in animal models \[[@pmed.1003188.ref051],[@pmed.1003188.ref052]\]; evidence from human data is limited. In this analysis, we observed consistent associations between same-day PM~2.5~ and various digestive diseases, including intestinal infection, esophageal disorders, gastritis and duodenitis, appendiceal conditions, liver diseases (*n* = 1,398,024), gastrointestinal hemorrhage (*n* = 811,588), and noninfectious gastroenteritis. Our findings strengthen the hypothesis that air pollution exposure adversely affects certain diseases of the digestive system, which should be fully considered in policy making aimed at protecting public health from air pollution.

We also found a robust positive association between PM~2.5~ and hospitalizations for diseases of the genitourinary system. A Chinese biopsy series study found that long-term exposure to PM~2.5~ was associated with the odds for membranous nephropathy \[[@pmed.1003188.ref053]\]. Recent cohort studies in US veterans \[[@pmed.1003188.ref012],[@pmed.1003188.ref013]\] and Taiwanese residents \[[@pmed.1003188.ref014]\] reported that elevated levels of PM~2.5~ and other pollutants were associated with increased risk of incident chronic kidney disease, chronic kidney disease progression, and end-stage renal disease. In this analysis, we observed consistent associations between same-day PM~2.5~ and several genitourinary diseases, including nephritis, nephrosis, and renal sclerosis; chronic renal failure; and calculus of urinary tract. Our findings indicate that even being exposed to air pollution for a short time can have adverse effects on one's genitourinary system, highlighting the importance of prompt public health intervention, especially for susceptible populations.

In addition to the above, we found a robust positive association between PM~2.5~ and hospitalizations for diseases of the musculoskeletal system and connective tissue. Also noteworthy is that higher PM~2.5~ exposure was significantly associated with increased risk of hospitalization for crystal arthropathies, anemia, chronic ulcer of skin, and spondylosis, intervertebral disc disorders, and other back problems in both single- and 2-pollutant models, as well as anxiety, somatoform, dissociative, and personality disorders and conditions associated with dizziness or vertigo in single-pollutant models. Chronic ulcer of skin, which had a relatively small sample size (*n* = 61,605) among all minor disease categories, had one of the largest effect estimates of PM~2.5~ among all minor disease categories. Overall, these findings are novel---some associations are supported by previous studies, e.g., PM~2.5~ and anxiety disorders \[[@pmed.1003188.ref054]--[@pmed.1003188.ref056]\], while others are reported to our knowledge for the first time. Certain musculoskeletal diseases and mental disorders that were associated with PM~2.5~ in this study contribute to the global burden of disease especially in terms of nonfatal consequences. For example, low back pain has prevailed as the top cause of years lived with disability worldwide for nearly 3 decades \[[@pmed.1003188.ref057],[@pmed.1003188.ref058]\]. Our findings indicate that air pollution may be a novel risk factor for the diseases that were associated with particulate matter in this study, and has the potential to account for the unattributed disease burden \[[@pmed.1003188.ref059]\].

We estimated a substantial annual reduction in the number of hospital admissions and hospitalization expenses that would be attributable to an improvement in daily PM~2.5~ in China, indicating that the government should develop effective mitigation policies to reduce the burden of disease attributable to air pollution. According to the cause-specific estimates, 47.6% of reduced hospital admissions and 49.9% of reduced hospitalization expenses would be attributable to non-cardiorespiratory diseases. In contrast, a time-series study using mortality data in 272 Chinese cities reported that only 15.2% of premature deaths prevented by PM~2.5~ reduction would be attributable to non-cardiorespiratory diseases \[[@pmed.1003188.ref031]\]. It should be noted that our estimates are based on short-term associations between air pollution and daily hospital admissions, and thus are not comparable to estimates based on long-term associations, e.g., in the Global Burden of Disease Study \[[@pmed.1003188.ref005]\]; however, our estimates can be compared with those from studies of the same design \[[@pmed.1003188.ref031]\]. Therefore, the precise estimation of the morbidity burden attributable to air pollution in China and worldwide deserves further research.

The biological mechanisms underlying the associations between air pollution and cardiorespiratory diseases are relatively well understood. Epidemiological and toxicological studies have demonstrated that exposure to particulate air pollution may induce systemic inflammation and oxidative stress, cause autonomic imbalance favoring sympathetic tone, and activate the hypothalamic--pituitary--adrenal axis, leading to vasoconstriction, hypertension, tachycardia, reduced heart rate variability, increased plasma viscosity, dyslipidemia, vascular endothelial dysfunction, atherosclerosis progression, platelet aggregation, hypercoagulability, and increased thrombogenesis \[[@pmed.1003188.ref006],[@pmed.1003188.ref007],[@pmed.1003188.ref015]\]. One or more of these mechanistic pathways may be involved in the extrapulmonary effects of air pollution \[[@pmed.1003188.ref060],[@pmed.1003188.ref061]\]. Moreover, there are a series of hypotheses to explain the associations between air pollution and specific non-cardiorespiratory diseases, some of which have been supported by emerging clinical and experimental evidence. Short- and long-term exposures to PM~2.5~ and other air pollutants have been suggested to adversely affect glucose and insulin homeostasis, leading to glucose intolerance, decreased insulin sensitivity, increased serum lipid levels, and, finally, a higher risk of diabetes mellitus as well as other metabolic diseases \[[@pmed.1003188.ref016],[@pmed.1003188.ref045],[@pmed.1003188.ref062]\]. Air pollution exposure has been reported to be associated with several key factors in the pathophysiology of central nervous system diseases, including neuro-inflammation and oxidative stress, microglial activation, dopaminergic neuron damage, and cerebrovascular impairment \[[@pmed.1003188.ref046],[@pmed.1003188.ref047]\]. These pathways may also play an important role in the pathogenesis of mental and behavioral disorders \[[@pmed.1003188.ref054]--[@pmed.1003188.ref056]\]. Air pollutants can be transported to the gastrointestinal tract by either mucociliary clearance from the lungs or ingestion of polluted food and water, and may exert direct toxic effects on gastrointestinal epithelial cells and influence gut microbial composition, leading to increased intestinal permeability, altered intestinal immunity, and oxidative stress and inflammatory response \[[@pmed.1003188.ref010],[@pmed.1003188.ref063],[@pmed.1003188.ref064]\]. The skin, the largest and outermost organ of the body, may be adversely affected by pollutants via direct exposure from the air or indirect exposure from the systemic circulation \[[@pmed.1003188.ref065]\]. The kidney, a highly vascularized organ, is vulnerable to both macro- and microvascular dysfunction and thus is likely to be affected through the pathways of air-pollution-induced cardiovascular toxicity \[[@pmed.1003188.ref012],[@pmed.1003188.ref066]\]. Finally, we postulate that air pollution exposure may increase the pain of various conditions (e.g., renal colic caused by kidney stones and chronic back pain) through prostaglandin pathways. Prostaglandins are major proinflammatory mediators that can sensitize pain receptors \[[@pmed.1003188.ref067],[@pmed.1003188.ref068]\]. Increased levels of prostaglandins cause more pain. Recent animal and human studies have linked excessive prostaglandins with short- and long-term exposures to PM~2.5~ and other air pollutants \[[@pmed.1003188.ref067]--[@pmed.1003188.ref070]\]. Nevertheless, the exact biological mechanisms underlying the reported associations remain elusive and deserve further research.

This study has some strengths. First, by analyzing all causes of hospitalization rather than a few prespecified outcomes, and reporting all results, this study provides evidence for health effects of air pollution that may have been neglected due to lack of prior knowledge. Second, this study defined disease categories at 2 levels. The major disease categories were used to evaluate the overall health effects of air pollution on each organ system, while the minor disease categories were used to identify the specific diseases that can be triggered and/or exacerbated by air pollution exposure. Third, this study has the advantages of a large dataset with good internal consistency in data collection, good timeliness (2013--2017), and extensive geographical and population coverage (252 cities in China; all ages), ensuring the generalizability of our results to the Chinese population or other populations in similar settings. Fourth, this study also provides the exposure--response relationships between air pollution and cause-specific hospital admissions, which support the hypothesis that there is no safety threshold for the health effects of PM~2.5~ exposure, but there may be a safety threshold close to the background concentration of O~3~ for the effect of O~3~ exposure on respiratory diseases. The possible existence of a threshold for O~3~ has been suggested by several studies conducted in high-income countries \[[@pmed.1003188.ref004],[@pmed.1003188.ref043]\], and should be further investigated in low- and middle-income countries, where the evidence is still limited.

This study has some limitations. First, we used monitored ambient concentrations of air pollutants as the proxy for personal exposures, leading to exposure measurement errors that are expected to bias the effect estimates toward null \[[@pmed.1003188.ref071]\]. Second, we cannot rule out the possibility of misclassifications resulting from diagnostic or coding errors in this large-scale nationwide dataset. Generally, the more specific the diagnostic categories that are used, the greater the likelihood of outcome misclassification. The diagnosis coding accuracy for the minor disease categories may thus be lower than that for the major disease categories. Therefore, our results concerning minor disease categories should be interpreted with caution. Future studies based on medically reviewed outcome data are warranted to confirm our findings. Third, our data cannot distinguish between scheduled and unscheduled hospitalizations. Including scheduled hospital admissions (e.g., planned surgeries), which are inherently unrelated to air pollution, is expected to reduce the estimation precision. However, a general-practitioner-based referral system is not available in China \[[@pmed.1003188.ref019],[@pmed.1003188.ref020]\]. Hospital visits and admissions are generally unscheduled and are on a first-come, first-served basis. Therefore, the impact of scheduled hospitalizations on our results is expected to be minor. Fourth, we did not have data on the chemical composition or emission sources of particulate matter, hindering us from further research. Fifth, we cannot estimate the long-term risk related to air pollution under the time-series analysis design. Studies of other designs (e.g., cohort studies) should be conducted to entirely understand the hazardous effects of air pollution, as well as replications of this work in other populations to confirm the external validity of our results.

Conclusions {#sec013}
-----------

This study provides a comprehensive picture of the associations between short-term exposure to main air pollutants and cause-specific risk of hospital admission in China over a wide spectrum of human diseases. Our analysis showed that air pollution exposure was associated with increased risk of hospitalization for diseases of multiple organ systems, including certain diseases of the digestive, musculoskeletal, and genitourinary systems; many of these associations are important but still not fully recognized. This study also evaluated potential effect modifiers and exposure--response relationships between air pollution and hospitalization. These results can inform policy making aimed at protecting public health from air pollution in China.
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Comments from the reviewers:

Reviewer \#1: Gu and colleagues conducted a national time-series study on the association between air pollution and cause-specific hospital admissions in China. It is ambitious to include a vast number of cause-specific endpoints in one manuscript, but the rationale and biological plausibility should be better presented. The analytic approaches seems sound, and the draft is well prepared. Some of the major conclusions have just been reported in several recent publications (e.g. Tian et al, BMJ 2019, Plos Med 2019). I have several major concerns in data source and methodology, which need to be clarified further. There are other minor points that need to be fixed or improved. My detailed comments are as follows:

1\. Line 90, more information is needed for the data collection, i.e. is it a public available dataset that can be accessed and supervised? The website or URL of it?

2\. Line 97, how were the cases diagnosed in the first place? The diagnosed cause of diseases upon hospital admission may be from the discharge diagnosis. In addition, hospital admission is quite dependent on local medical resources (hospital beds, etc) and personal social economic status (health insurance for instance). These factors may introduce large uncertainty in the analysis and may eventually bias the results (such as lag pattern). The authors should add a through discussion on this and compare the situation between China and developed countries.

3\. Line 102, my biggest concern for this analysis is the rationale and biological plausibility for the association between air pollution and the endpoints examined. Although the authors cited previous papers that examined the same endpoints or exposures, there\'s inadequate information provided on the specific mechanisms for all the major categories included in the analysis in both Introduction and Discussion. Please amend. Data availability and clinical meaningfulness is not a convincing objective.

4\. Line 108, more information is need for the exposures. For example, is this based on fixed-site monitoring stations? How many monitors are there for each city? If such information is provided in the Appendix, please incorporate and indicate. How about missing rates? I assume that will be a lot of missing in exposure time-series, especially for the early years and the less-developed areas.

5\. Line 116, how were the statistical models determined? If modeling specification is based on previous studies, please cite them and explain the rationale to general readers. Why were the over dispersed Poisson family used, rather than the quasi-Poisson conjunction? What models exactly? Is linear regression models used?

6\. Line 118, how were the degree of freedom determined in the first place? By AIC, BIC or other model fitting statistics?

7\. Line 121, why two terms of temperature and relative humidity were added? I assume this would introduce large collinearity in the models and cause overfitting. Is the best-of-fit modelling strategy applied? What model-fitting statistics were used?

8\. Line 129, the main lag should be determined by how the models are fitted, especially for multi-center studies, rather than based on which to generate the largest effect estimate.

9\. Line 134, how were north and south regions separated in China, by latitude?

10\. Line 137, there\'s too little information on how the exposure-response curves were pooled, please provide a brief introduction. In particular, did the authors use a linear model for plotting, how is non-linearity considered for the associations between exposure and outcome?

11\. Line 138, please indicate what dfs were used for each parameters, and why did the authors select these dfs rather than other ranges? For example, why only 8 to 12 for year, while other studies have reported 4 to 12. This should be stated for temperature and relative humidity as well.

12\. Line 140, in the disease burden calculation, one critical problem is that this was inherently a time-series study on the short-term associations, thus it is not applicable to estimate the annual (long-term) reduction in hospital admissions. The authors should better clarify this. How is the information acquired on the average cost for each hospitalization in China? I assume this would vary a lot by cities.

13\. Line 165, why to select different lags for PM2.5 and ozone? How to interpret the results if different lags were set?

14\. Line 282, why were the estimates of this study lower than those from developed countries?

15\. Line 286, why could this study provide evidence for the chronic health effects of air pollution?

16\. Line 293, Tian\'s study was on ER visits, thus may not be appropriate for this case.

17\. Again, please add through discussions on the rationales between air pollution and various endpoints.

18\. Line 337, the first strength of this study may stand only if there\'s solid supporting evidence for the hypothesized association.

19\. Line 340, the generalizability of this study is largely dependent on whether the hospital admissions are representative enough for the local population. This should be mentioned before in the Methods, in that how many population (maybe in percentage) did the class 3 hospital serve? How many hospitals are there in each city, etc.

Reviewer \#2: The manuscript describes a large multi-city time series study from China on air pollution exposure and numerous hospitalization (morbidity) endpoints. The study made use of national standardized reporting of hospitalization discharges. The data analysis methodology was generally state-of-the-art for multi-site time series and accounted for the multiple exploratory comparisons undertaken. Additional sensitivity analyses were important, although not as helpful in some respects as they might have been - see below. Finally, the manuscript was generally very well-written. I have some concerns, however.

Critique:

1\. An important first question, given the plethora of published time series studies, including multi-city time series studies, some of which are from China, is whether yet another one is needed. This study has some features to recommend it. The large array of outcomes, while not without issues (see points 3-5, below), is unique, and the large number of hospitalization counts ensures adequate power for addressing many of the outcomes. There may be others that the authors want to highlight to address the specific contributions that justify yet another time series study.

2\. Although I may have missed it, there was no mention that the hospitalizations included only those for unscheduled urgent admissions. Scheduled hospitalizations, such as those for \"maintenance chemotherapy/radiotherapy,\" which interestingly showed an association with PM2.5, should not be included in this analysis.

3\. The authors argue that including the large array of hospitalization endpoints was a strength of the study, and have addressed concerns about multiple comparisons. However, with such a large array of outcomes showing statistically significant associations, the issue of biologic plausibility becomes a more serious concern. Interestingly, the authors raise the issue of negative controls when they note: \"\... negative controls such as female infertility, which has no plausible relation to air pollution\" (line 280). One could argue, in fact, that many of the outcomes showing statistically significant associations could be characterized in the same way. For example, there would seem to be tenuous plausibility for calculus of the urinary tract, and certainly none for \"maintenance chemotherapy/radiotherapy,\" as noted above. It\'s possible that all of the outcomes demonstrating significant effects in this analysis, as the authors suggest, are providing novel insights into the far more global impact of air pollution on health than previously thought, but this seems very unlikely. And while systemic inflammation and oxidative stress as a unifying \"downstream\" mechanism underlying all air pollution health effects covers a wide swath of diseases, there remain many outcomes for which even this is a tenuous argument, many that heretofore we might even have thought to include as negative controls. Although currently there is no solution to this dilemma, the authors should consider including some very convincing negative controls, such as accidents, for example, which were not included in the current analysis.

4\. One of the hazards of including as many endpoints as were included in this study is the possibility that there may have been a very small number of daily counts for many of the endpoints, and in some cases no counts in some of the cities. This would result in very uncertain estimates of effect in those cases in the first stage of the analysis. The meta-analytic step presumably somewhat accounts for this by giving less weight to endpoints in cities with uncertain estimates. It would nevertheless be helpful to see the distribution of daily counts of each of the endpoints (not merely IQR as in Table 2) as a supplemental table in order to assess the magnitude of this issue.

5\. A related issue is that the more specific the diagnostic categories that are used, the greater the likelihood of outcome misclassification. That is, while diagnosis coding accuracy for a general endpoint such as cardiovascular disease is good, diagnosis coding accuracy for more specific endpoints such as pulmonary heart disease or acute bronchitis, for example, are much more suspect. Because of the focus on a large array of very specific outcomes in this study, the likelihood of misclassification of the outcomes is great. The impact of such errors in the outcome when the outcome is binary would be to bias to the null. The authors recognize this, but perhaps somewhat more elaboration in the Discussion is needed.

6\. It is well known that reporting the effect estimate from the single day with the largest estimate of effect is biased and results in overestimation of the true effects. The current preferred approach is to employ an unconstrained distributed lag model to estimate the unbiased net cumulative effect over several days, an approach which is arguably also more in line with current pathophysiologic understanding. However, in the current setting, for PM2.5 at least, it seems the choice to report only current day effects is not an unreasonable choice given the day lag structure presented for many of the endpoints (Figure S2). This is not the case for ozone, however. Figure S3 shows that there is no clear single lag that stands out, in contrast to the picture with PM2.5. Even for respiratory disease, the primary condition for which effects of ozone were observed, the choice of lag is not clear - positive effects are observed for day lags 0 through 3 with that for lag 1 being the largest, and with day lag 3 being the longest lag reported. For circulatory disease, alternatively, the current day has the largest estimate of ozone effect. The justification for reporting only lag 1 effects for ozone is therefore suspect. The results for ozone, at least, are an example of why employing a distributed lag model is preferable. Reporting only day 1 lag effects for ozone and respiratory disease, the lag with the largest effect estimate (Figure S3), is not recommended. For most of the other endpoints, reporting only the lag 1 effects for ozone (Fig S3) is an odd choice.

7\. The concentration-response function (CRF) plots (Figure 3) show 95% confidence bounds that are constrained to have bounds of zero at the point where the endpoint and the PM2.5 axes are both zero. This makes little sense given that there are likely no days with extremely low PM2.5 concentrations in Chinese cities. One expects the confidence bounds to be tightest around the median of the PM2.5 concentration distribution where most of the data lie. Admittedly, what the authors have shown is commonplace in the literature, but it\'s a practice that should be avoided because it is not informative.

8\. The authors have repeated (line 230) what is commonly stated in the literature regarding the absence of an apparent threshold concentration where no effects can be identified. While this may be the case for PM2.5 and for most of the endpoints, importantly it does not appear to be the case for ozone and respiratory disease (Figure S9), the endpoint of most relevance for ozone. A threshold in the range of 40-50 ug/m3 of ozone seems to be present. The conclusions need to therefore be qualified to reflect this.

9\. The results of the several sensitivity analyses were reassuring. However, the sensitivity analysis relating to the degrees of freedom (df) for the time trend is not adequate. Here the authors have reported results of varying the time trend df in the range from 8 to 12/year. This range is far too narrow to assess sensitivity of results to varying df and to be assured that the chosen df are adequate. Clearly, using too few df runs the risk of not adequately removing time trends, while it has been argued that using too many df runs the risk of encroaching on the effect of the air pollutant. Given that the time scale of interest for pollutant effects is from one to a few days, with 12 df/year that corresponds to a knot for approximately each month, there seems little danger that the pollutant effect would be encroached upon by even more than 12 df. The authors should be encouraged to report results of a sensitivity analysis with time trend df ranging from 6 to 18/year.
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2 Apr 2020

Dear Dr. Gu,

Thank you very much for re-submitting your manuscript \"Ambient air pollution and cause-specific risk of hospital admissions in China: A nationwide time-series study\" (PMEDICINE-D-19-04229R1) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Apr 09 2020 11:59PM.

Sincerely,

Clare Stone, PhD

Managing Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)
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Requests from Editors:

At line 526 I think you mean to say risk of admission (rather \"risk of disease\")? Please amend.

Can you please check the given link for data as this doesn't seem to retrieve the suggested link, for me at least ((<https://spms.hqms.org.cn/>).

Please use the \"Vancouver\" style for reference formatting, and see our website for other reference guidelines <https://journals.plos.org/plosmedicine/s/submission-guidelines#loc-references> (specifically, no bold or ital font and only the first 6 authors names followed by et al)

Comments from Reviewers:

Reviewer \#2: I am generally very pleased with the authors\' thorough responses to review, the responsiveness to reviewers\' suggestions and the revisions to the manuscript. My major issues have been addressed. A couple of comments:

1\. I would have liked to have seen the results of an analysis employing a larger number of df/year for time trend, but the authors\' response provided justification for not doing that and it seems unlikely that there would have been substantial changes in the effect estimates with less smoothing.

2\. It\'s unfortunate that the authors were unable to exclude non-urgent admissions, but their response was reassuring.

Minor:

Line 225. It\'s probably not appropriate to indicate \"According to the suggestion of reviewers, \...\" in the body of a revised manuscript, but perhaps that decision could be left to the editors.

Sverre Vedal

Reviewer \#3: The authors have addressed all my points.

Michael Dewey

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003188.r004
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8 Jul 2020

Dear Mr. Gu,

On behalf of my colleagues and the academic editor, Dr. Yuming Guo, I am delighted to inform you that your manuscript entitled \"Ambient air pollution and cause-specific risk of hospital admissions in China: A nationwide time-series study\" (PMEDICINE-D-19-04229R2) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Clare Stone, PhD

Managing Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)
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